Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics is offering $75.0 million of its Class A common stock in an underwritten primary equity offering. The company may also grant the underwriters a 30-day option to purchase up to an additional $11.25 million of Class A shares.
As of September 30, 2025, Contineum had 23,099,173 shares of Class A common stock and 6,083,338 shares of non-voting Class B common stock outstanding. The company expects that net proceeds from this offering, combined with existing cash, cash equivalents and marketable securities, will fund operations through mid-2029, with a primary focus on advancing its PIPE-791 program, supporting other research and development, and general corporate purposes, including potential complementary product or technology acquisitions without binding commitments.
Contineum is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology indications and remains an emerging growth and smaller reporting company. It does not expect to pay cash dividends in the foreseeable future and cautions that future share issuances and sales, including under its at-the-market program after a 30-day pause, could pressure the market price of its Class A common stock.
Contineum Therapeutics is offering $75.0 million of its Class A common stock in an underwritten primary equity offering. The company may also grant the underwriters a 30-day option to purchase up to an additional $11.25 million of Class A shares.
As of September 30, 2025, Contineum had 23,099,173 shares of Class A common stock and 6,083,338 shares of non-voting Class B common stock outstanding. The company expects that net proceeds from this offering, combined with existing cash, cash equivalents and marketable securities, will fund operations through mid-2029, with a primary focus on advancing its PIPE-791 program, supporting other research and development, and general corporate purposes, including potential complementary product or technology acquisitions without binding commitments.
Contineum is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology indications and remains an emerging growth and smaller reporting company. It does not expect to pay cash dividends in the foreseeable future and cautions that future share issuances and sales, including under its at-the-market program after a 30-day pause, could pressure the market price of its Class A common stock.
Contineum Therapeutics, Inc. reported that on December 8, 2025 it submitted details of its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis to the ClinicalTrials.gov Protocol Registration and Results System, with posting to follow PRS approval.
The 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled study will evaluate once-daily PIPE-791 in about 324 IPF patients, focusing on safety and tolerability and the change from baseline in absolute forced vital capacity at week 26.
The company’s trial design and launch strategy draw on prior regulatory engagement and completed Phase 1 studies, and it expects to begin the trial internationally and add countries as regulatory approvals are obtained, with completion anticipated in June 2028.
Contineum Therapeutics, Inc. reported that on December 8, 2025 it submitted details of its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis to the ClinicalTrials.gov Protocol Registration and Results System, with posting to follow PRS approval.
The 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled study will evaluate once-daily PIPE-791 in about 324 IPF patients, focusing on safety and tolerability and the change from baseline in absolute forced vital capacity at week 26.
The company’s trial design and launch strategy draw on prior regulatory engagement and completed Phase 1 studies, and it expects to begin the trial internationally and add countries as regulatory approvals are obtained, with completion anticipated in June 2028.
Contineum Therapeutics, Inc. (CTNM) reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis. The company furnished this press release as Exhibit 99.1 to the report and incorporated it by reference, indicating that detailed clinical results are contained in that exhibit.
Contineum Therapeutics (CTNM) reported a Q3 2025 net loss of $12.8 million, driven by research and development of $11.0 million and general and administrative expense of $3.9 million. Interest income was $2.0 million, partially offsetting operating costs.
Liquidity remains strong with $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025. Management states these resources are sufficient for at least 12 months. During the quarter, the company activated its at-the-market program, selling 3,241,110 Class A shares at a weighted average price of $6.04 for $19.0 million in net proceeds.
Pipeline execution continued. PIPE-791 completed Phase 1 and Phase 1b PET work; a global Phase 2 in idiopathic pulmonary fibrosis is planned for Q4 2025, and an exploratory Phase 1b chronic pain trial began dosing in March 2025 with topline data expected in the first half of 2026. PIPE-307, partnered with J&J, has a fully enrolled Phase 2 RRMS trial with topline results targeted for Q4 2025, and J&J initiated a Phase 2 study in major depressive disorder in December 2024.
Contineum Therapeutics, Inc. furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into any Securities Act registration statement unless specifically identified.
Contineum Therapeutics reported that a pharmacokinetic–pharmacodynamic relationship between exposure to its investigational drug PIPE-791 and LPA1 brain receptor occupancy (RO) was confirmed in both healthy volunteers and progressive multiple sclerosis (PrMS) patients. Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement after dosing. The company states its planned Phase 2 proof-of-concept doses are expected to provide >90% target coverage at trough with once-daily dosing.
The filing also contains customary forward-looking statements and risk disclosures noting that these early clinical results may not predict future outcomes and that development, regulatory, and funding risks could affect plans.
Contineum Therapeutics reported that a pharmacokinetic–pharmacodynamic relationship between exposure to its investigational drug PIPE-791 and LPA1 brain receptor occupancy (RO) was confirmed in both healthy volunteers and progressive multiple sclerosis (PrMS) patients. Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement after dosing. The company states its planned Phase 2 proof-of-concept doses are expected to provide >90% target coverage at trough with once-daily dosing.
The filing also contains customary forward-looking statements and risk disclosures noting that these early clinical results may not predict future outcomes and that development, regulatory, and funding risks could affect plans.
Contineum Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reports that the Master Fund directly holds 699,486 shares of Class A common stock, representing 3.2% of the outstanding class based on 21,625,223 shares. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, each disclose the same beneficial ownership because they may be deemed to beneficially own the Master Fund's position. The filing shows no sole voting or dispositive power and only shared voting and dispositive power for the reported shares. The filing states the position was not acquired to influence control of the issuer.
Franklin Resources, Inc., its subsidiary Franklin Advisers, Inc., and related control persons filed Amendment No. 1 to Schedule 13G for Contineum Therapeutics, Inc. (CTNM) covering Class A common stock (CUSIP 21217B100) as of 30 June 2025.
- Shares owned: 1,698,825.
- Percent of outstanding class: 8.9%.
- Voting & dispositive power: Sole power resides with Franklin Advisers; no shared power reported.
- Individuals Charles B. Johnson and Rupert H. Johnson, Jr. report 0 shares.
- The largest underlying account, Franklin Biotechnology Discovery Fund, holds 1,100,717 shares (5.8%).
- Filers certify the stake is held in the ordinary course of business with no intent to influence control.
No financial results, transactions, or additional corporate events are disclosed in this filing.